» Articles » PMID: 17548110

Non-small Cell Lung Cancer Cells Produce a Functional Set of Complement Factor I and Its Soluble Cofactors

Overview
Journal Mol Immunol
Date 2007 Jun 6
PMID 17548110
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The complement system is important for protection from invading pathogens, removal of waste products and guidance of the immune response. Furthermore, complement can be also targeted to cancer cells. However, membrane-bound inhibitors over-expressed by certain types of tumor cells restrict the cytotoxic activity of complement. Herein we report that non-small cell lung cancer (NSCLC) cells produce soluble complement inhibitors factor I (FI) and C4b-binding protein (C4BP). FI is a serine protease capable of degrading the activated complement components C3b and C4b, whilst C4BP acts as its cofactor. Furthermore, NSCLC cells express membrane-bound regulators and shed membrane cofactor protein (MCP), which shares cofactor function with C4BP. Secretion of FI from NSCLC cells was higher than previously reported for any non-hepatic source and FI produced by these cells could efficiently support cleavage of C3b and C4b. In vitro functional assays revealed that additional FI significantly decreased C3 deposition and complement-dependent lysis, particularly when cofactors were added. Our results demonstrate that soluble inhibitors produced by NSCLC cells may provide further protection from complement beyond the level ensured by membrane-bound inhibitors and, as such, contribute to the aggressive phenotype of these lung cancer cells.

Citing Articles

Molecular Biology of Cancer-Interplay of Malignant Cells with Emerging Therapies.

Boussios S, Sheriff M, Ovsepian S Int J Mol Sci. 2024; 25(23).

PMID: 39684799 PMC: 11642048. DOI: 10.3390/ijms252313090.


Anti-HER2 Cancer-Specific mAb, HMab-250-hG, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab.

Suzuki H, Ohishi T, Tanaka T, Kaneko M, Kato Y Int J Mol Sci. 2024; 25(15).

PMID: 39125956 PMC: 11313270. DOI: 10.3390/ijms25158386.


Complement system in Anti-CD20 mAb therapy for cancer: A mini-review.

Gao Y Int J Immunopathol Pharmacol. 2023; 37:3946320231181464.

PMID: 37357623 PMC: 10331094. DOI: 10.1177/03946320231181464.


Identification of two molecular subtypes and a novel prognostic model of lung adenocarcinoma based on a cuproptosis-associated gene signature.

Zhou J, Chen D, Zhang S, Wang C, Zhang L Front Genet. 2023; 13:1039983.

PMID: 36712848 PMC: 9877306. DOI: 10.3389/fgene.2022.1039983.


RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review.

Faruqui T, Khan M, Akhter Y, Khan S, Rafi Z, Saeed M Int J Mol Sci. 2023; 24(1).

PMID: 36613714 PMC: 9820344. DOI: 10.3390/ijms24010266.